Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	114.09	49.3	87.7	10.61	1.41
Short-Term Investments	84.1	187.26	22.41	-	-
Cash & Short-Term Investments	198.19	236.57	110.11	10.61	1.41
Cash Growth	-16.22%	114.85%	937.60%	653.16%	-
Prepaid Expenses	7.16	12.54	2.7	0.46	0.06
Restricted Cash	-	-	-	0.05	-
Total Current Assets	205.35	249.1	112.81	11.12	1.47
Property, Plant & Equipment	0.05	-	-	-	-
Long-Term Investments	-	2.48	-	-	-
Long-Term Deferred Charges	0.4	-	1.6	0	-
Other Long-Term Assets	0.1	0.05	0.03	-	0.02
Total Assets	205.9	251.64	114.44	11.13	1.49
Accounts Payable	0.48	0.6	1.91	0.76	0.53
Accrued Expenses	14.17	9.88	6.16	4.29	0.05
Short-Term Debt	-	-	-	-	4.5
Total Current Liabilities	14.65	10.48	8.07	5.05	5.08
Total Liabilities	14.65	10.48	8.07	5.05	5.08
Common Stock	0.01	0	0	0	0.01
Additional Paid-In Capital	493.77	365.86	0.54	0.09	-
Retained Earnings	-302.52	-124.71	-52.81	-23.01	-3.6
Total Common Equity	191.26	241.15	-52.27	-22.93	-3.6
Shareholders' Equity	191.26	241.15	106.38	6.07	-3.6
Total Liabilities & Equity	205.9	251.64	114.44	11.13	1.49
Total Debt	-	-	-	-	4.5
Net Cash (Debt)	198.19	236.57	110.11	10.61	-3.09
Net Cash Growth	-16.22%	114.85%	937.60%	-	-
Net Cash Per Share	4.08	6.54	21.31	2.13	-0.67
Filing Date Shares Outstanding	49.84	49.63	40.86	5.44	4.63
Total Common Shares Outstanding	49.82	41.13	6.42	5.44	4.63
Working Capital	190.71	238.62	104.74	6.07	-3.62
Book Value Per Share	3.84	5.86	-8.14	-4.21	-0.78
Tangible Book Value	191.26	241.15	-52.27	-22.93	-3.6
Tangible Book Value Per Share	3.84	5.86	-8.14	-4.21	-0.78

Source: S&P Capital IQ. Standard template. Financial Sources.